Ian Smith

Summary

Affiliation: Royal Brompton Hospital
Country: UK

Publications

  1. pmc Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
    A E Ring
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 91:2012-7. 2004
  2. ncbi request reprint Trastuzumab
    Ian E Smith
    Breast Unit, Department of Medicine, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Womens Health (Lond Engl) 1:161-9. 2005
  3. ncbi request reprint Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies
    I E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Anticancer Drugs 12:S3-10. 2001
  4. ncbi request reprint Preoperative/neoadjuvant medical therapy for early breast cancer
    I E Smith
    Breast Unit, Royal Marsden NHS Trust, London, UK
    Lancet Oncol 2:561-70. 2001
  5. ncbi request reprint Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    I E Smith
    Royal Marsden National Health Service Trust, London and Surrey, UK
    J Clin Oncol 19:1336-43. 2001
  6. ncbi request reprint Aromatase inhibitors in breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    N Engl J Med 348:2431-42. 2003
  7. ncbi request reprint Phase II studies of pemetrexed in metastatic breast and gynecologic cancers
    Ian Smith
    Medical Oncologist Royal Marsden Hospital, London, United Kingdom
    Oncology (Williston Park) 18:63-5. 2004
  8. ncbi request reprint A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
    I E Smith
    Royal Marsden Hospital, Fulham Road, Lonson SW3 6JJ, UK
    Ann Oncol 15:751-8. 2004
  9. ncbi request reprint Hormonal therapy: introduction
    Ian E Smith
    The Royal Marsden Hospital, Sutton, Surrey, UK
    Breast 12:S1. 2003
  10. ncbi request reprint Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:289-93. 2003

Detail Information

Publications128 found, 100 shown here

  1. pmc Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
    A E Ring
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 91:2012-7. 2004
    ....
  2. ncbi request reprint Trastuzumab
    Ian E Smith
    Breast Unit, Department of Medicine, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Womens Health (Lond Engl) 1:161-9. 2005
    ..Recently, benefits for trastuzumab have also been shown in the neoadjuvant and adjuvant setting...
  3. ncbi request reprint Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies
    I E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Anticancer Drugs 12:S3-10. 2001
    ..Thus, Herceptin represents a significant development in the management of HER2-positive breast cancer...
  4. ncbi request reprint Preoperative/neoadjuvant medical therapy for early breast cancer
    I E Smith
    Breast Unit, Royal Marsden NHS Trust, London, UK
    Lancet Oncol 2:561-70. 2001
    ..This would lead to individualised treatment for each patient, and would allow much more rapid assessment of new drugs than is currently possible with adjuvant therapy trials...
  5. ncbi request reprint Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    I E Smith
    Royal Marsden National Health Service Trust, London and Surrey, UK
    J Clin Oncol 19:1336-43. 2001
    ..We have carried out a multicenter randomized trial comparing three versus six courses of chemotherapy...
  6. ncbi request reprint Aromatase inhibitors in breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    N Engl J Med 348:2431-42. 2003
  7. ncbi request reprint Phase II studies of pemetrexed in metastatic breast and gynecologic cancers
    Ian Smith
    Medical Oncologist Royal Marsden Hospital, London, United Kingdom
    Oncology (Williston Park) 18:63-5. 2004
    ..Ongoing and future studies will establish optimal dosing regimens of pemetrexed and potential benefits of vitamin supplementation in the settings of metastatic breast cancer and gynecologic malignancies...
  8. ncbi request reprint A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
    I E Smith
    Royal Marsden Hospital, Fulham Road, Lonson SW3 6JJ, UK
    Ann Oncol 15:751-8. 2004
    ..To compare the efficacy of continuous infusional 5-fluorouracil (5-FU)-based chemotherapy against conventional bolus chemotherapy in the preoperative treatment of patients with large operable early breast cancer...
  9. ncbi request reprint Hormonal therapy: introduction
    Ian E Smith
    The Royal Marsden Hospital, Sutton, Surrey, UK
    Breast 12:S1. 2003
  10. ncbi request reprint Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:289-93. 2003
    ..These results indicate that letrozole is more active than tamoxifen both as neoadjuvant therapy and as first-line treatment in advanced disease. They support the importance of current adjuvant trials comparing the two treatments...
  11. ncbi request reprint Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen
    Ian E Smith
    Royal Marsden Hospital, Surrey, England, UK
    Breast 13:S3-9. 2004
    ..This review will examine the published data, discuss ongoing trials, and address the question of how to best integrate the aromatase inhibitors into adjuvant treatment...
  12. pmc Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
    Paul Ellis
    Guy s and St Thomas NHS Trust, London, UK
    Lancet 373:1681-92. 2009
    ..The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration...
  13. pmc Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
    Trevor Powles
    Parkside Oncology, London, UK
    Breast Cancer Res 8:R13. 2006
    ....
  14. doi request reprint Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Natl Cancer Inst Monogr 2011:120-3. 2011
    ..It provides a unique opportunity for detailed study of the determinants of response and resistance to estrogen deprivation as well as testing the role of presurgical therapy for improved biomarker-based estimates of prognosis...
  15. doi request reprint Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial
    Hatem A Azim
    Jose Baselga, Memorial Sloan Kettering Cancer Center, NY James G Greger Jr, GlaxoSmithKline, Collegeville, PA Hatem A Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles Phuong Dinh, Breast International Group, Brussels Peter Vuylsteke, Sint Elisabeth Hospital, Namur, Belgium Dominique Agbor tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain Christian Jackisch, Kilinikum Offenbach, Offenbach Bahriye Aktas, Kliniken Essen Mitte, Evang,
    J Clin Oncol 31:4504-11. 2013
    ....
  16. ncbi request reprint Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
    S Chua
    Royal Marsden Hospital, London, UK
    Ann Oncol 16:1435-41. 2005
    ..Vinorelbine is active and well tolerated against advanced breast cancer but there are no published efficacy studies in early breast cancer. We have therefore carried out a randomised phase III neoadjuvant trial in operable breast cancer...
  17. ncbi request reprint Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
    Stephen R D Johnston
    Department of Medicine Breast Unit, The Royal Marsden NHS Trust, 233 Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:173-81. 2005
    ..This article reviews the pre-clinical rationale for this strategy and the clinical trials in this area...
  18. doi request reprint Time trends in the outcome of elderly patients with breast cancer
    Sarah Hughes
    The Royal Marsden Hospital, Surrey, United Kingdom
    Breast J 14:158-63. 2008
    ..More clinical trials for older women are needed, if the benefits of recent advances in the management of this disease are to be extended to the over 70s. These data should, however, act as a benchmark for future audits...
  19. ncbi request reprint Adjuvant endocrine therapy for early breast cancer
    Claudia Andreetta
    Royal Marsden Hospital, Fulham Road, London, UK
    Cancer Lett 251:17-27. 2007
    ..Issues including the timing of administration (up-front or sequential), the duration of the therapy and the role of biomarkers such as PgR and HER2 in optimal selection remain unresolved...
  20. ncbi request reprint 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  21. pmc Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial
    R H De Boer
    Department of Medicine, Royal Marsden NHS Trust, London, UK
    Br J Cancer 79:1514-8. 1999
    ..Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial...
  22. pmc Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
    P A Ellis
    Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 71:366-70. 1995
    ..The schedule should also be assessed as primary (neoadjuvant) chemotherapy before radical radiotherapy for locally advanced NSCLC in a randomised trial...
  23. doi request reprint Platinum-based chemotherapy in triple-negative breast cancer
    B Sirohi
    Breast Unit, Royal Marsden NHS Foundation Trust, London, UK
    Ann Oncol 19:1847-52. 2008
    ..We present our long-term results with platinum-based chemotherapy for TN breast cancer...
  24. ncbi request reprint Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy
    Marina Parton
    Breast Unit, Royal Marsden NHS Trust and Institute of Cancer Research, London SW3 6JJ, United Kingdom
    Clin Cancer Res 8:2100-8. 2002
    ..Therefore, the relationship between key components of this machinery was examined in primary human breast carcinomas before and 24 h after the initiation of chemotherapy...
  25. ncbi request reprint Factors determining outcome after third line chemotherapy for metastatic breast cancer
    Udai Banerji
    The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, London, UK
    Breast 16:359-66. 2007
    ..Patients who do not respond to the first two lines of chemotherapy should be considered for clinical trials or supportive care...
  26. pmc Medical treatment of early breast cancer. IV: neoadjuvant treatment
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:223-4. 2006
  27. pmc A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma
    A Saini
    Royal Marsden Hospital NHS Trust, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 83:853-7. 2000
    ..Confirmation of this effect and further investigation is underway in a randomized phase III trial and in laboratory models...
  28. ncbi request reprint Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
    A Ring
    Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, United Kingdom
    J Clin Oncol 21:4540-5. 2003
    ..This retrospective analysis aimed to identify whether breast cancer patients receiving radiotherapy alone following a complete clinical remission (cCR) to neoadjuvant chemotherapy had a worse outcome than those treated with surgery...
  29. doi request reprint Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Anastasia Constantinidou
    Breast Unit, Royal Marsden Hospital, London UK and Institute of Cancer Research, London, UK
    Breast 20:S158-61. 2011
    ..Meanwhile there is already enough circumstantial evidence to justify anti-HER2 therapy alone in selected patients for whom chemotherapy is contraindicated...
  30. ncbi request reprint Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer
    Monica Arnedos
    Breast Unit, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res Treat 112:1-4. 2008
    ..We have reviewed a series of patients with early breast cancer treated with accelerated 2-weekly paclitaxel without routine GCSF to assess its need...
  31. ncbi request reprint Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom
    Susan Shanley
    Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Clin Cancer Res 12:7033-8. 2006
    ..To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003...
  32. ncbi request reprint Is there still a role for neoadjuvant therapy in breast cancer?
    Catherine Shannon
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Crit Rev Oncol Hematol 45:77-90. 2003
    ..The potential for biological surrogate markers of response to predict for long-term outcome may allow individualisation of systemic treatment and the rapid assessment of new drugs in early breast cancer...
  33. ncbi request reprint Mechanisms of resistance to aromatase inhibitors
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 95:167-72. 2005
    ..Collection of resistant biopsy tissues from patients is important to determine if this mechanism is clinically relevant...
  34. pmc Medical treatment of early breast cancer. I: adjuvant treatment
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:34-7. 2006
  35. ncbi request reprint A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer
    R H De Boer
    The Royal Marsden NHS Trust, London, UK
    Ann Oncol 13:889-94. 2002
    ....
  36. pmc Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer
    J R Hardy
    Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 60:764-6. 1989
    ..The high incidence of symptomatic relief seen in this study, even in the absence of objective response, suggests that moderate dose chemotherapy may have a role in the palliation of NSCLC...
  37. pmc A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer
    P A Ellis
    Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 71:1315-8. 1995
    ....
  38. pmc A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, London, UK
    Br J Cancer 100:305-10. 2009
    ..Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules...
  39. pmc Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer
    A Urruticoechea
    Department of Medicine Breast Unit, Royal Marsden NHS Trust, London and Surrey, England
    Br J Cancer 92:475-9. 2005
    ..3). Toxicity profile was mild. This platinum-based chemotherapy is an effective, well-tolerated and low-cost regimen for patients with MBC, including those pretreated with anthracyclines...
  40. ncbi request reprint Neoadjuvant chemotherapy for breast cancer
    F Sapunar
    Breast Unit, Royal Marsden Hospital, London, UK
    Ann Med 32:43-50. 2000
    ..Biological predictors reflecting changes in apoptosis and/or proliferation may in the future offer the best surrogate markers for long-term outcome, and trials have recently begun in this area...
  41. pmc Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma
    R Mendes
    Lung Unit, Department of Haematology, The Royal Marsden Hospital NHS Trust, Downs Road, Sutton, SM2 5PT, UK
    Br J Cancer 86:336-41. 2002
    ..SRL172 can be given safely into tumour deposits and the pleural cavity in patients with malignant mesothelioma and we have established the dose for phase II testing...
  42. pmc A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer
    T F Hickish
    Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 77:1966-70. 1998
    ..MVP, an effective palliative regimen for NSCLC, is also active against SCLC with low toxicity and merits comparison with more toxic conventional schedules...
  43. ncbi request reprint The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
    E Andreopoulou
    Lung Unit, Royal Marsden Hospital, Surrey, UK
    Ann Oncol 15:1406-12. 2004
    ..We have analysed prospectively collected data to evaluate a frequently used palliative chemotherapy regimen...
  44. doi request reprint Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial
    Ian Smith
    Breast Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
    Breast Cancer Res Treat 130:133-43. 2011
    ..In the absence of progression, continuation of single-agent bevacizumab appears to be a reasonable approach, with minimal toxicity and the possibility of long-term disease control...
  45. doi request reprint Sternal/para-sternal resection for parasternal local recurrence in breast cancer
    Jill Noble
    Breast Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, UK
    Breast 19:350-4. 2010
    ..This can result in substantial morbidity and mortality. Chest wall resection is well-documented for palliation and local control in chest wall relapse; an extension of this surgery is parasternal or sternal resection...
  46. pmc Medical treatment of early breast cancer. III: chemotherapy
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:161-2. 2006
  47. ncbi request reprint Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
    Trevor Powles
    Royal Marsden National Health Service Trust, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 20:3219-24. 2002
    ..Given to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone metastases...
  48. ncbi request reprint Goals of treatment for patients with metastatic breast cancer
    Ian Smith
    The Royal Marsden Hospital, London, UK
    Semin Oncol 33:S2-5. 2006
    ....
  49. pmc Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
    P N Mainwaring
    Department of Medicine, Royal Marsden NHS Trust, Sutton, UK
    Br J Cancer 76:1636-9. 1997
    ....
  50. ncbi request reprint A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer
    D W Miles
    Guy's Hospital, London, UK
    Eur J Cancer 37:1366-71. 2001
    ..These results suggest that pemetrexed has significant antitumour activity in advanced breast cancer with responses in patients who had previously received anthracyclines and taxoids...
  51. pmc How should cancer presenting as a malignant pleural effusion be managed?
    H Bonnefoi
    Lung Unit, Royal Marsden NHS Trust, Sutton, Surrey, UK
    Br J Cancer 74:832-5. 1996
    ..In this series the thoracic CT led to a diagnosis of lung primary in 34% of the cases. Other radiological examinations and bronchoscopy were unhelpful. Chemotherapy achieved symptom relief in 78% of patients...
  52. ncbi request reprint Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC)
    R K Gregory
    Royal Marsden Hospital, Sutton, UK
    Clin Oncol (R Coll Radiol) 13:483-7. 2001
    ..The MVCarbo regimen resulted in response rates and survival rates equivalent to those seen with standard MVP and, as such, provides an acceptable outpatient alternative to this treatment...
  53. ncbi request reprint Breast cancer
    Alistair Ring
    Department of Medicine, Breast Unit, Royal Marsden Hospital, London, UK
    Cancer Chemother Biol Response Modif 22:545-61. 2005
  54. pmc Medical treatment of early breast cancer. II: endocrine therapy
    Ian Smith
    Royal Marsden Hospital, London
    BMJ 332:101-3. 2006
  55. ncbi request reprint Predictors of response to aromatase inhibitors
    Helen Anderson
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 106:49-54. 2007
    ..Analysis of multiple gene expression changes over a short treatment period may also have potential clinical utility for prediction of response...
  56. pmc Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial
    Sally Moore
    Centre for Cancer and Palliative Care Studies, Institute of Cancer Research, Royal Marsden Hospital, London SW3 6JJ
    BMJ 325:1145. 2002
    ..To assess the effectiveness of nurse led follow up in the management of patients with lung cancer...
  57. ncbi request reprint Progression of endocrine therapies for breast cancer: where are we headed?
    Monica Arnedos
    The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Expert Rev Anticancer Ther 7:1651-64. 2007
    ..A key question for all forms of endocrine therapy remains optimal duration. Evidence is emerging to suggest that, for some women, treatment should be continued for many years and perhaps lifelong...
  58. pmc Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens
    I E Smith
    Department of Computing and Information, Royal Marsden Hospital, London, UK
    Br J Cancer 67:801-5. 1993
    ..This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox...
  59. pmc Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
    C D Archer
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 89:1035-41. 2003
    ..Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer...
  60. ncbi request reprint The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway
    P V Murray
    Lung Unit, Department of Medicine, Sutton and Kent Cancer Centre, The Royal Marsden Hospital, Maidstone, Downs Road, Sutton, Surrey SM2 5PT, UK
    Lung Cancer 42:283-90. 2003
    ..Delays in diagnosis in the current UK system may be one reason for such discrepancy. To address this problem we set up a rapid diagnostic system and compared it to the conventional method of investigations in a pilot randomised trial...
  61. pmc Basal-like breast carcinomas: clinical outcome and response to chemotherapy
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London, UK
    J Clin Pathol 59:729-35. 2006
    ..Patients with basal-like breast carcinomas (BLBC) are reported to have a shorter disease-free and overall survival...
  62. pmc A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer
    D I Jodrell
    Medical Breast Unit, Royal Marsden Hospital, London, UK
    Br J Cancer 63:794-8. 1991
    ..MMM is an active, well tolerated new chemotherapy regimen for advanced/metastatic breast carcinoma with an efficacy and toxicity spectrum very similar to CMF...
  63. pmc Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
    P J Ross
    Lung Unit, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK
    Br J Cancer 90:1905-11. 2004
    ..03, RR=1.92) and an independent predictor of progression-free survival in patients with SCLC (P=0.01, RR=1.43). In conclusion, weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival...
  64. pmc Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen
    H Bonnefoi
    Breast Unit, Royal Marsden Hospital, London, UK
    Br J Cancer 73:391-6. 1996
    ..Infusional ECarboF is a highly active, well-tolerated, outpatient regimen effective against advanced/metastatic breast cancer and now warrants evaluation against conventional chemotherapy in high-risk early breast cancer...
  65. ncbi request reprint Does timing of adjuvant chemotherapy for early breast cancer influence survival?
    C Shannon
    Breast Unity, Royal Marsden Hospital, United Kingdom
    J Clin Oncol 21:3792-7. 2003
    ..We have addressed this question from a large, single-center database in which the majority of patients received anthracyclines...
  66. ncbi request reprint Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? Treatment decision-making in advanced disease
    I E Smith
    The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London, UK
    Ann Oncol 19:vii51-7. 2008
  67. pmc EPIC: an effective low toxicity regimen for relapsing lymphoma
    T Hickish
    Lymphoma Unit, Royal Marsden Hospital, Sutton, Surrey, London, UK
    Br J Cancer 68:599-604. 1993
    ..The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality...
  68. pmc Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer
    J C Newby
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 71:1237-42. 1995
    ..02) and overall survival (P = 0.03) when measured by this immunohistochemical assay, but was not significant when measured by ligand-binding assay...
  69. pmc Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    P V Murray
    Lung Unit, Department of Medicine, The Royal Marsden Hospital, Sutton and Kent Cancer Centre, Maidstone, UK
    Br J Cancer 83:1418-24. 2000
    ..14-2.58) in those without the antibody (P = 0.02). This study, the largest homogeneous group so far looking at p53-Ab in SCLC, suggests that p53 antibody detection may have a role in predicting outcome in this type of cancer...
  70. ncbi request reprint Aromatase inhibitors and male breast cancer
    E Arriola
    Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London, UK
    Clin Transl Oncol 9:192-4. 2007
    ..Here we report a case of a male patient with metastatic breast cancer treated with letrozole who achieved clinical response associated with a decrease in blood oestradiol levels...
  71. pmc Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas
    P A Ellis
    Academic Department of Biochemistry, Royal Marsden NHS Trust, Sutton, UK
    Br J Cancer 73:640-3. 1996
    ..This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival materials...
  72. pmc Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia
    Br J Cancer 94:358-62. 2006
    ....
  73. ncbi request reprint Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment
    M O Leach
    CRC Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    NMR Biomed 11:314-40. 1998
    ....
  74. pmc Survival from breast cancer in England and Wales up to 2001
    A Leary
    Breast Unit, Royal Marsden Hospital, NHS Foundation Trust, Fulham Road, London SW3 6JJ, London, UK
    Br J Cancer 99:S56-8. 2008
  75. pmc Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer
    P N Mainwaring
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 51:34-7. 1998
    ..The use of biotinylated nucleotides to identify DNA strand breaks is a commonly reported method of estimating cells numbers undergoing apoptosis; however, investigators report inconsistent results for a variety of reasons...
  76. pmc A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer
    J L Mansi
    Breast Unit, Royal Marsden Hospital, Sutton, Surrey
    Br J Cancer 64:593-7. 1991
    ..Lonidamine appears to be active against advanced breast cancer and its low toxicity would allow combination studies with chemotherapy...
  77. pmc A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients
    M Dowsett
    Department of Biochemical Endocrinology, Royal Marsden Hospital, London, UK
    Br J Cancer 62:834-7. 1990
    ..We conclude that the slow release formulation of leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75 rather than 7.5 mg dose...
  78. pmc Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects
    I L Crighton
    Department of Medicine, Royal Marsden Hospital, London, UK
    Br J Cancer 60:644-8. 1989
    ....
  79. pmc Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques
    A E Ring
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 92:906-12. 2005
    ..001) or IMS (83 vs 48%, P<0.001).The use of a multimarker real-time RT-PCR assay was therefore found to be the most sensitive technique for the detection of circulating epithelial cells in the blood of patients with breast cancer...
  80. pmc In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth
    M J Everard
    Section of Medicine, Royal Marsden Hospital, Belmont, Surrey, UK
    Br J Cancer 65:388-92. 1992
    ..Therefore D-Phe5SP appears to have more potent antiproliferative effects in tumour cells than normal cells, suggesting a role for this analogue in tumour treatment...
  81. doi request reprint Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
    M Arnedos
    Department of Medicine, Breast Unit, The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Ann Oncol 20:1948-52. 2009
    ....
  82. ncbi request reprint Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London and Sutton, London, UK
    Ann Oncol 16:1632-8. 2005
    ..The IMPACT trial evaluated neoadjuvant therapy with anastrozole or tamoxifen alone, or a combination. The comparative effects of these treatments on serum lipids and bone resorption were assessed...
  83. pmc Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients
    M E R O'Brien
    Department of Medicine, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 95:1632-6. 2006
    ..Most deaths were due to disease progression in the palliative setting. We practice this form of audit each quarter and feed back to the treating teams so that deaths are discussed and practice monitored...
  84. pmc Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
    J Y Pierga
    Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
    Br J Cancer 96:341-51. 2007
    ..2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages...
  85. pmc The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
    S R Johnston
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    Br J Cancer 75:804-9. 1997
    ..The drug's reduced agonist activity may, in part, explain these observations and indicate a preferable biochemical profile for breast cancer treatment...
  86. pmc Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer
    V M Macaulay
    Lung Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Br J Cancer 64:451-6. 1991
    ..In summary we saw little correlation between SSR expression and growth inhibition by octreotide, either in vitro or clinically...
  87. ncbi request reprint Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry 32:291-300. 1998
    ..3-11.3% by flow cytometry) and between different phases of treatment, and should provide a useful tool for further research on this process in solid tumours...
  88. ncbi request reprint High incidence of HER-2 positivity in inflammatory breast cancer
    M Parton
    Breast Unit, Royal Marsden Hospital Trust and Institute of Cancer Research, Fulham Rd, London SW3 6JJ, UK
    Breast 13:97-103. 2004
    ..Early HER-2 directed therapy (such as the monoclonal antibody trastuzumab) as a part of multimodal treatment may improve outcome in this poor prognosis cancer...
  89. ncbi request reprint Breast cancer and pregnancy
    A E Ring
    Guy s Hospital, London, UK
    Ann Oncol 16:1855-60. 2005
    ..However, few breast surgeons or oncologists develop expertise in this area owing to the rarity of the association...
  90. ncbi request reprint Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
    S R Johnston
    Department of Medicine, Royal Marsden Hospital and Institute of Cancer Research, London, England
    Clin Cancer Res 5:251-6. 1999
    ..These observations support the need for further evaluation of these markers in breast tumors as predictors of TAM resistance...
  91. ncbi request reprint Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
    David S P Tan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 111:27-44. 2008
    ....
  92. doi request reprint Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  93. ncbi request reprint A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007
    ..We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial...
  94. ncbi request reprint Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London, UK
    Cancer 112:710-7. 2008
    ....
  95. ncbi request reprint Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
    Sanjay Popat
    J Natl Cancer Inst 97:858; author reply 858-9. 2005
  96. doi request reprint Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  97. doi request reprint Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women
    Marina Parton
    Breast Unit, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 26:745-52. 2008
  98. ncbi request reprint The evolution of adjuvant endocrine therapy: developments since St Gallen 2005
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast 16:S4-9. 2007
    ....
  99. ncbi request reprint Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)
    Ander Urruticoechea
    Institut Catala d Oncologia, Hospital Duran i Reynalds, Gran Via km 2 7 L Hospitalet de Llobregat, Barcelona, Spain
    Breast Cancer Res Treat 110:411-6. 2008
    ..We report an audit of our experience with the luteinising hormone-releasing hormone agonist, goserelin, to achieve transient ovarian suppression during chemotherapy as a means of preserving ovarian function...
  100. doi request reprint The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 14:2656-63. 2008
    ..We investigated the effects of anastrozole and tamoxifen over time on serum VEGF and sVEGFR-1...
  101. ncbi request reprint Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    Trevor J Powles
    Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, UK
    J Natl Cancer Inst 99:283-90. 2007
    ..We report the blinded 20-year follow-up (median follow-up = 13 years) of the Royal Marsden trial to identify any long-term prevention of breast cancer associated with tamoxifen treatment...